AI Stock Analysis - Salarius Pharmaceuticals (SLRX)
Analysis generated February 13, 2026.
Salarius Pharmaceuticals is a biotechnology company focused on developing targeted cancer therapies. Their primary research revolves around epigenetic oncology, which seeks to exploit the modulation of gene expression. The company endeavors to develop therapies that address significant gaps in the current cancer treatment landscape.
Stock Alerts - Salarius Pharmaceuticals (SLRX)
 |
Salarius Pharmaceuticals | February 3 Employee Rating is down by 8.7% over the last month. |
|
Salarius Pharmaceuticals | January 7 Price is up by 12.1% in the last 24h. |
|
Salarius Pharmaceuticals | January 6 Price is up by 6.5% in the last 24h. |
|
Salarius Pharmaceuticals | January 5 Price is down by -12.4% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Salarius Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Employee Rating | 84 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,888 | Sign up | Sign up | Sign up |
| X Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 10 | Sign up | Sign up | Sign up |
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need.
| Price | $0.84 |
| Target Price | Sign up |
| Volume | 6,050,000 |
| Market Cap | $4.9M |
| Year Range | $0.54 - $14.99 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 1,100 | -1,100 | -870,000 | -870,000 | -1.814 |
| Q2 '25 | 0 | 1,100 | -1,100 | -960,000 | -960,000 | -0.450 |
| Q1 '25 | 0 | 1,100 | -1,100 | -1.7M | -1.7M | -1.016 |
| Q4 '24 | 4,400 | 2,200 | 2,200 | -1.5M | -1.5M | -1.010 |
| Q3 '24 | 0 | 1,100 | -1,100 | -970,000 | -1M | -11.400 |
Insider Transactions View All
| HANISH ARNOLD C filed to sell 5,000 shares at $0.6. January 2 '26 |
| HANISH ARNOLD C filed to buy 5,015 shares at $0.7. November 24 '25 |
| Rosenblum Mark J filed to buy 20,177 shares at $0.8. November 20 '25 |
| Lieber Jonathan I filed to buy 37,500 shares at $0.2. June 8 '22 |
Similar companies
Read more about Salarius Pharmaceuticals (SLRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Salarius Pharmaceuticals
The Market Cap of Salarius Pharmaceuticals is $4.9M.
Currently, the price of one share of Salarius Pharmaceuticals stock is $0.84.
The SLRX stock price chart above provides a comprehensive visual representation of Salarius Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Salarius Pharmaceuticals shares. Our platform offers an up-to-date SLRX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Salarius Pharmaceuticals (SLRX) does not offer dividends to its shareholders. Investors interested in Salarius Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Salarius Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
